104 related articles for article (PubMed ID: 38776734)
1. Evaluation of tubulin β-3 and 5 hydroxy-methyl cytosine as diagnostic and prognostic markers in malignant melanoma.
Katarzyna L; Kyriakos O; Linda V; Ingrid S; Petra W; Karin Ö
Ann Diagn Pathol; 2024 Oct; 72():152332. PubMed ID: 38776734
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations.
Rodić N; Zampella J; Sharma R; Burns KH; Taube JM
J Cutan Pathol; 2015 Nov; 42(11):807-14. PubMed ID: 26239102
[TBL] [Abstract][Full Text] [Related]
3. 5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms.
Lee JJ; Vilain RE; Granter SR; Hu NR; Bresler SC; Xu S; Frank AH; Mihm MC; Saw RP; Fletcher CD; Scolyer RA; Murphy GF; Lian CG
J Cutan Pathol; 2017 Mar; 44(3):249-255. PubMed ID: 28032662
[TBL] [Abstract][Full Text] [Related]
4. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of tubulin β-3 as a novel senescence-associated gene in melanocytic malignant transformation.
Orfanidis K; Wäster P; Lundmark K; Rosdahl I; Öllinger K
Pigment Cell Melanoma Res; 2017 Mar; 30(2):243-254. PubMed ID: 28024114
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of dual 5-hydroxymethylcytosine/Melan-A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: An effective first-line test for the workup of sentinel lymph node specimen.
Siref AB; Huynh CAT; Balzer BL; Frishberg DP; Essner R; Shon W
J Cutan Pathol; 2019 Apr; 46(4):261-266. PubMed ID: 30632191
[TBL] [Abstract][Full Text] [Related]
7. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.
Krengel S; Grotelüschen F; Bartsch S; Tronnier M
J Cutan Pathol; 2004 Jan; 31(1):1-7. PubMed ID: 14675278
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Histopathologic Characteristics of Melanocytic Lesions on the Volar Skin Without Typical Dermoscopic Patterns.
Mikoshiba Y; Minagawa A; Koga H; Yokokawa Y; Uhara H; Okuyama R
JAMA Dermatol; 2019 May; 155(5):578-584. PubMed ID: 30865233
[TBL] [Abstract][Full Text] [Related]
9. 5-Hydroxymethylcytosine Expression in Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma.
Pavlova O; Fraitag S; Hohl D
J Invest Dermatol; 2016 Dec; 136(12):2453-2461. PubMed ID: 27456754
[TBL] [Abstract][Full Text] [Related]
10. Proliferative activity of primary cutaneous melanocytic tumours.
Kuwata T; Kitagawa M; Kasuga T
Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909
[TBL] [Abstract][Full Text] [Related]
11. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.
Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR
Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543
[TBL] [Abstract][Full Text] [Related]
12. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
13. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
Mehregan DR; Hamzavi I
Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
[TBL] [Abstract][Full Text] [Related]
14. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
16. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
17. β-Catenin nuclear expression discriminates deep penetrating nevi from other cutaneous melanocytic tumors.
de la Fouchardière A; Caillot C; Jacquemus J; Durieux E; Houlier A; Haddad V; Pissaloux D
Virchows Arch; 2019 May; 474(5):539-550. PubMed ID: 30756182
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas.
Chen PL; Chen WS; Li J; Lind AC; Lu D
Mod Pathol; 2013 Jan; 26(1):44-53. PubMed ID: 22899289
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
20. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
Rothberg BE; Moeder CB; Kluger H; Halaban R; Elder DE; Murphy GF; Lazar A; Prieto V; Duncan LM; Rimm DL
Mod Pathol; 2008 Sep; 21(9):1121-9. PubMed ID: 18552823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]